siRNA Delivery with Lipid-based Systems: Promises and Pitfalls

被引:51
作者
Foged, Camilla [1 ]
机构
[1] Univ Copenhagen, Fac Pharmaceut Sci, Dept Pharmaceut & Analyt Chem, DK-2100 Copenhagen, Denmark
关键词
siRNA; RNAi; delivery; lipid; liposomes; immune activation; SMALL INTERFERING RNA; TOLL-LIKE RECEPTORS; INNATE IMMUNE-RESPONSE; IN-VIVO DELIVERY; GENE DELIVERY; INTRACELLULAR DELIVERY; TARGETED DELIVERY; DENDRITIC CELLS; DRUG-DELIVERY; CATIONIC LIPOSOMES;
D O I
10.2174/156802612798919141
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
A key hurdle for the further development of RNA interference (RNAi) therapeutics like small interfering RNA (siRNA) is their safe and effective delivery. Lipids are promising and versatile carriers because they are based on Nature's own building blocks and can be provided with properties which allow for protection of the siRNA, steric stabilization, targeting, membrane fusion and triggered drug release. At present a variety of lipid-based transfectants for siRNA delivery have been used for in vitro and in vivo purposes. The majority bears a cationic charge to electrostatically complex the siRNA into more hydrophobic lipoplexes, which promote passage of the siRNA across cellular membrane barriers, especially when lipids are added that facilitate membrane fusion. Despite these attractive features, siRNA delivery vehicles are facing a number of challenges such as the limited delivery efficiency in vivo, toxicity and non-specific stimulation of the immune system. To optimally design and tailor the lipidic systems for siRNA delivery, better insight is needed into the mechanisms of cell delivery. More specifically, further clarification is need regarding the nature of cell surface interactions, routes of internalization, passage of intracellular membranes, and mechanisms of immune activation. This review provides an overview of the main constituents currently employed in lipid-based siRNA carriers, and recent research into improvements of cell delivery. In addition, pitfalls related to immune activation and side effects are discussed, and possible ways to overcome them are highlighted.
引用
收藏
页码:97 / 107
页数:11
相关论文
共 128 条
[1]
Abrams M.T., 2009, MOL THER
[2]
RNA-dependent RNA polymerases, viruses, and RNA silencing [J].
Ahlquist, P .
SCIENCE, 2002, 296 (5571) :1270-1273
[3]
Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity [J].
Akhtar, Saghir ;
Benter, Ibrahim .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (2-3) :164-182
[4]
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics [J].
Akinc, Akin ;
Zumbuehl, Andreas ;
Goldberg, Michael ;
Leshchiner, Elizaveta S. ;
Busini, Valentina ;
Hossain, Naushad ;
Bacallado, Sergio A. ;
Nguyen, David N. ;
Fuller, Jason ;
Alvarez, Rene ;
Borodovsky, Anna ;
Borland, Todd ;
Constien, Rainer ;
de Fougerolles, Antonin ;
Dorkin, J. Robert ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
John, Matthias ;
Koteliansky, Victor ;
Manoharan, Muthiah ;
Nechev, Lubomir ;
Qin, June ;
Racie, Timothy ;
Raitcheva, Denitza ;
Rajeev, Kallanthottathil G. ;
Sah, Dinah W. Y. ;
Soutschek, Juergen ;
Toudjarska, Ivanka ;
Vornlocher, Hans-Peter ;
Zimmermann, Tracy S. ;
Langer, Robert ;
Anderson, Daniel G. .
NATURE BIOTECHNOLOGY, 2008, 26 (05) :561-569
[5]
Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver [J].
Akinc, Akin ;
Goldberg, Michael ;
Qin, June ;
Dorkin, J. Robert ;
Gamba-Vitalo, Christina ;
Maier, Martin ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
Rajeev, Kallanthottathil G. ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
Roehl, Ingo ;
Leshchiner, Elizaveta S. ;
Langer, Robert ;
Anderson, Daniel G. .
MOLECULAR THERAPY, 2009, 17 (05) :872-879
[6]
LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS [J].
ALLISON, AC ;
GREGORIADIS, G .
NATURE, 1974, 252 (5480) :252-252
[7]
Barron L. G., 1999, NONVIRAL VECTORS GEN, P229
[8]
Lipoplex-mediated gene delivery to the lung occurs within 60 minutes of intravenous administration [J].
Barron, LG ;
Gagné, L ;
Szoka, FC .
HUMAN GENE THERAPY, 1999, 10 (10) :1683-1694
[9]
BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
[10]
Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses [J].
Bitko V. ;
Barik S. .
BMC Microbiology, 1 (1) :1-11